Pharmaceutical Composition Comprising Enavogliflozin for Cardiovascular Aging Diseases
Summary
The USPTO published patent application US20260097060A1 for a pharmaceutical composition comprising enavogliflozin as an active ingredient for preventing or treating cardiovascular aging diseases. The invention demonstrates effects in preventing endothelial dysfunction caused by vascular endothelial senescence. The application was filed on September 27, 2023, under Application No. 19115424.
What changed
The USPTO published a patent application (US20260097060A1) for a pharmaceutical composition containing enavogliflozin specifically directed to preventing or treating cardiovascular aging diseases. The claimed invention exploits enavogliflozin's ability to prevent endothelial dysfunction caused by vascular endothelial senescence, representing a novel therapeutic application for this SGLT2 inhibitor compound.
Pharmaceutical companies developing or marketing SGLT2 inhibitors and cardiovascular treatments should evaluate this patent for freedom-to-operate implications. Companies conducting research in cardiovascular aging, endothelial function, or diabetes-related cardiovascular applications face potential patent clearance requirements. The patent's broad claim scope covering cardiovascular aging diseases may affect product development strategies and commercialization timelines.
What to do next
- Conduct freedom-to-operate analysis for enavogliflozin cardiovascular applications
- Review patent claims for potential licensing opportunities
- Monitor patent prosecution for scope limitations
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN FOR PREVENTING OR TREATING CARDIOVASCULAR AGING DISEASES
Application US20260097060A1 Kind: A1 Apr 09, 2026
Inventors
Sun-Hwa Park, Joon Seok Park, Ji-Soo Choi, Hye Young Ji, Min-Ho Oak, Ju-Young Ko, Saugat Shiwakoti, Dhakal Bikalpa
Abstract
The present invention relates to a pharmaceutical composition for use in preventing or treating cardiovascular aging diseases, comprising enavogliflozin as an active ingredient. Enavogliflozin of the present invention exhibits excellent effects in the prevention and treatment of endothelial dysfunction caused by vascular endothelial senescence, and cardiovascular aging diseases related thereto.
CPC Classifications
A61K 31/7048 A61P 9/00
Filing Date
2023-09-27
Application No.
19115424
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.